Jci_page_head_homepage_01 Jci_page_head_homepage_02
Maira G.R. Pitta, Audrey Romano, Sandrine Cabantous, Sandrine Henri, Awad Hammad, Bouréma Kouriba, Laurent Argiro, Musa el Kheir, Bruno Bucheton, Charles Mary, Sayda Hassan El-Safi, Alain Dessein
Published in Volume 119, Issue 8
J Clin Invest. 2009; 119(8):2379–2387 doi:10.1172/JCI38813
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 4
IL-23, IL-6, and IL-1β production in cultures of PBMCs from subjects from the 3 clinical groups.

(A) IL-6 and IL-1β levels were higher in cultures of PBMCs from gp1 subjects than in those of cells from gp2 subjects, whereas no difference was observed for IL-23. Cultures were stimulated as described in Figure 2A. (B) PBMCs from KA subjects produced small amounts of IL-17 and IL-22, even in the presence of normal to high levels of the regulatory cytokines IL-6, IL-1β, and IL-23. IL-23, IL-6, and IL-1β levels in cultures (from gp1 and gp2) were assigned to 3 classes of equal size, and IL-17 and IL-22 levels are presented for each cytokine class. A nonparametric Kruskal-Wallis test showed a significant increase of IL-17 (P < 0.03) in increasing IL-23, IL-6, and IL-1β classes in cultures of PBMCs from resistant subjects. No significant increase of IL-17 was observed with increasing concentrations of IL-6 and IL-1β in cultures of PBMCs from gp2 subjects, whereas IL-17 did increase (P < 0.001) with increasing IL-23 concentrations in the same cultures. IL-22 increased (P < 0.05) with increasing IL-23, IL-6, and IL-1β concentrations in cultures of PBMCs from gp1 and gp2 subjects. The data presented are the arithmetic means ± SEM.